Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination

This study seeks to evaluate the comparative bioavailability of etoricoxib/betamethasone tablets 90 mg/0.25 mg test drug, administered in fixed combination vs. etoricoxib tablets 90 mg (Arcoxia®) reference drug, and betamethasone solution 50 mg/100 mL (Celestone® Pediatric) reference drug, administered individually, in a single dose, to 42 healthy mexican research subjects of both genders, under fasting conditions.

NCT Number	NCT07454369
Lead Sponsor	Laboratorios Silanes S.A. de C.V.
Conditions	Healthy
Enrollment	42 participants
Start Date	2022-10-24
Primary Completion	2022-11-25 (estimated)
Study Completion	2023-01-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-06